1495P - Sunitinib therapy in advanced alveolar soft part sarcomas

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anti-Cancer Agents & Biologic Therapy
Soft Tissue Sarcomas
Presenter Hanna Kosela
Authors H.M. Kosela1, K. Wiater1, T. Switaj1, A. Klimczak1, S. Falkowski1, P. Rutkowski2
  • 1Soft Tissue/bone Sarcoma And Melanoma, MSC Memorial Cancer Centre and Institute Maria Sklodowska-Curie, 02-781 - Warsaw/PL
  • 2Soft Tissue/bone Sarcoma And Melanoma, MSC Memorial Cancer Centre and InstituteMaria Sklodowska-Curie, PL-02-781 - Warsaw/PL

Abstract

Background

Alveolar soft part sarcoma (ASPS) is a rare entity making up < 1% of soft tissue sarcomas (STS). It is characterized by slow, indolent growth but with a high frequency of metastatic disease especially to lungs. Chemotherapeutic regimens used for the treatment of other soft tissue sarcomas lack efficacy in ASPS. The purpose of our analysis was to assess sunitinib activity in ASPS.

Methods

Since July 2009, 7 patients with metastatic ASPS have been treated with sunitinib continuous daily dosing 37,5mg (1 pts started treatment at 50mg/d on a 4/2 week schedule). All patients' initial performance status according to ECOG was 0-1. Median age at time of diagnosis was 23 yrs (range 18-57), gender distribution M/F was 1/6. Primary localization of the tumor was: lower extremity (3), trunk (2), retroperitoneum (1), pelvis (1). Primary tumor size ranged from 5 to 12 cm (median 7cm). All patient had unresectable metastases to the lungs. 57% of the patients were previously treated with standard chemotherapy. Median time from diagnosis to start of sunitinib therapy was 6 months (range: 2-156). Responses were evaluated after 2 months from baseline, then every 3 months by CT scan and/or MRI, according to RECIST criteria.

Results

At the time of present analysis 3 of the patient continue therapy. After 2 months of treatment 2 patients had RECIST PR, 5 SD. Median PFS was 15 months with 86% patients free of progression of the disease at 6 months. Median therapy duration was 18 months (range: 5-31). Median OS was 15 months; 3 patients died due to disease progression at the time of analysis. One of the patients had SD after 4 months of treatment, interrupted treatment for 3 months and experienced progression of the disease, after restarting therapy she again gained SD lasting 12 months. Toxicity was rather moderate. All the patients experienced some side effects, 4 patients (57%) had toxicity grade 3/4 CTC. The common treatment toxicity was neutropenia, hypothyroidism, arterial hypertension, hand and foot syndrome. 2 patients required dose reduction. There was one death related to the treatment (sepsis).

Conclusion

Our analysis shows efficacy of sunitinib in patients with advanced ASPS.

Disclosure

P. Rutkowski: honoraria: Pfizer and Novartis.

All other authors have declared no conflicts of interest.